JLP-2002

Jeil Pharmaceutical Co., Ltd. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	JLP-2002
Sponsor	Jeil Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder (PHASE3)
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JLP-2002 CI brief — competitive landscape report
JLP-2002 updates RSS · CI watch RSS
Jeil Pharmaceutical Co., Ltd. portfolio CI